Vbi Vaccines Inc buy marge
Zusammenfassung
Diese Einschätzung wurde am 27.11.18 mit einem Endkurs von 1,52 € beendet. Stark abwärts ging es für die BUY Einschätzung von marge zu Vbi Vaccines Inc mit einer Rendite von -61,06 %. marge hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Vbi Vaccines Inc | - | - | - | - |
| iShares Core DAX® | 2,59 % | -1,86 % | 13,24 % | 16,87 % |
| iShares Nasdaq 100 | 3,55 % | -2,06 % | 38,29 % | 45,90 % |
| iShares Nikkei 225® | 0,69 % | -8,70 % | 17,51 % | 2,76 % |
| iShares S&P 500 | 2,21 % | -1,99 % | 27,63 % | 42,95 % |
Kommentare von marge zu dieser Einschätzung
In der Diskussion Vbi Vaccines Inc diskutieren
VBIV continues making progress towards starting a Phase 3 trial for hepatitis B
Summary
VBI Vaccines continues making progress towards starting a Phase 3 trial for hepatitis B.
The recent addition to the Russell 2000 should provide more visibility to the investment community for the small biotech.
The recent stock selloff provides an opportunity to own the biotech at a reasonable value.
As with most small biotechs, VBI Vaccines (VBIV) trades in a volatile manner. The stock now trades some 35% from the yearly highs of $6.60 despite some promising developments for the stock during june.
Last week, the small biotech got positive feedback from the FDA that Sci-B-Vac will not require additional clinical studies to support the Phase 3 study. The company now plans to kickoff the IND in the U.S. and CTAs in Europe and Canada in the 2H of the year.
The key to the story is that the third-generation hepatitis B vaccine has already demonstrated safety and efficacy in over 300,000 patients. The vaccine is approved in the home country Israel of SciVac and 14 other countries.